Press Releases

Date Title and Summary Additional Formats
Toggle Summary A Tribute to Alex Barkas View HTML
Toggle Summary Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
John F. Crowley provides perspectives and recommendations to Committee on treating rare and neglected pediatric diseases and promoting the development of new treatments-
View HTML
Toggle Summary Amicus Therapeutics (FOLD) President and Chief Executive Officer to Ring the NASDAQ Stock Market Closing Bell
Company to Celebrate Initial Public Offering On NASDAQ
View HTML
Toggle Summary Amicus Therapeutics Achieves Target Enrollment in Second Phase 3 Fabry Monotherapy Study
56 Patients Now Randomized to Switch from Enzyme Replacement Therapy (ERT) to Migalastat HCl or to Remain on ERT Final Enrollment Expected Ahead of Year-End Target CRANBURY, N.J. , Oct. 22, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of
View HTML
Toggle Summary Amicus Therapeutics Acquires Gene Therapy Portfolio of Ten Clinical and Pre-Clinical Stage AAV Programs in Neurologic Lysosomal Storage Disorders
License with Nationwide Children’s Hospital ( NCH ) through the Acquisition of Celenex (NCH Spinout) Establishes Amicus as Leading Gene Therapy Company in Neurologic Lysosomal Storage Disorders (LSD) with Potential to Transform the Lives of 10,000+ Children with Fatal Genetic Diseases              
View HTML
Toggle Summary Amicus Therapeutics Added to NASDAQ Biotechnology Index
CRANBURY, N.J. , May 21, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that the Company was added to the NASDAQ Biotechnology Index (Nasdaq:NBI) (Nasdaq:XNBI) after the
View HTML
Toggle Summary Amicus Therapeutics Added to NASDAQ Biotechnology Index (NBI)
CRANBURY, N.J. , Dec. 22, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that the Company was added to the NASDAQ Biotechnology Index (Nasdaq:NBI) (Nasdaq:XNBI), effective
View HTML
Toggle Summary AMICUS THERAPEUTICS ADDS GLENN P. SBLENDORIO TO BOARD OF DIRECTORS
Company Makes Executive and Management Appointments
View HTML
Toggle Summary Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
CRANBURY, N.J., Jan 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced the election of Sol J. Barer, Ph.D., to its Board of Directors. Dr. Barer currently serves as Chairman and Chief Executive Officer of Celgene Corporation.
View HTML
Toggle Summary Amicus Therapeutics Advances Chaperone-Enzyme Replacement Therapy (ERT) Combination Platform in Pompe Disease
Phase 2 AT2220-ERT Co-Administration and Preclinical AT2220-ERT Co-Formulation Studies Presented at LDN WORLD Symposium Next-Generation ERT Advancing in Preclinical Studies Conference Call on February 15, 2013 at 11:30am ET CRANBURY, N.J. , and ORLANDO, Fla. , Feb.
View HTML